Article Text

Download PDFPDF
Reply: further studies needed before using renin-angiotensin-aldosterone system blockade for atrial fibrillation prevention in hypertrophic cardiomyopathy
  1. Chen-Yu Huang,
  2. Lian-Yu Lin
  1. Division of Cardiology, Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan
  1. Correspondence to Dr Chen-Yu Huang, Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei 100, Taiwan; chenyo2007{at}gmail.com

Statistics from Altmetric.com

The Authors’ reply

We thank Dr Ramchand and his colleagues for valuable comments1 on our paper from the retrospective data from National Health Insurance Research Database in Taiwan.2

Several key points should be emphasised in interpretation of the observational study. First, although we did not know how many patients received cardiac MRI to establish or confirm the diagnosis of hypertrophic cardiomyopathy (HCM), it is uncommon to mistake hypertensive cardiac disease for HCM. Second, among patients with HCM without hypertension in our study, use of ACE inhibitors/angiotensin …

View Full Text

Footnotes

  • Contributors LYL is responsible for the overall content as a guarantor, and contributed to the conception and design of the work, acquisition and interpretation of the data and critical revision of the manuscript for important intellectual content. CYH contributed to the conception and design of the work, analysis and interpretation of data for the work, drafting of the manuscript and revising the manuscript.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles